In vitro fertilisation with preimplantation genetic testing: the need for expanded insurance coverage
Year: 2020
Type: article
Abstract: Technological advances in genetic testing have enabled prospective parents to learn about their risk of passing a genetic condition to their future children. One option for those who want to ensure that their biological children do not inherit a genetic condition is to create embryos through in vitro fertilisation (IVF) and use a technique called preimplantation genetic testing (PGT) to screen embryos for genetic abnormalities before implantation. Unfortunately, due to its high cost, IVF-with-PGT is out of reach for the vast majority of Americans. This article addresses an issue that has been underexplored in the medical ethics literature: the lack of insurance coverage for IVF-with-PGT.Within the US system, a key concept in insurance is that of medically necessary care, which broadly consists of diagnostic services and treatment services. In this article, I argue that IVF-with-PGT could be classified as either a diagnostic service or as a treatment service. To make this case, I show that IVF-with-PGT is similar to other types of services that are often covered by US insurance providers. In light of these similarities, I argue that the current system is inconsistent with respect to what is-and is not-covered by insurance. To promote consistency and fairness in coverage, like cases should be treated alike-starting with greater coverage for IVF-with-PGT.
Source: Journal of Medical Ethics
Author: Madison K Kilbride
Institution: University of Pennsylvania
Language: English
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W3052916089